Clinical Advancements in the Management of Familial Hypercholesterolemia

This special symposium was held at the 2013 NLA Annual Scientific Sessions this past May in Las Vegas, NV with audio and slide highlights captured for additional viewing. This activity defines HoFH and discusses the marked cardiovascular risk associated with this diagnosis. Please join our panel of expert faculty as they discuss the most efficacious options for screening and genetic testing to identify hidden, high-risk patients, and the most current therapeutic options for FH patients who are unable to reach their target LDL-C levels on statin therapy alone.


Patrick M. Moriarty, MD

Professor of Medicine
Atherosclerosis/LDL-Apheresis Ctr.
Division of Clinical Pharmacology
University of Kansas Medical Center
Kansas City, KS

James M. Backes, PharmD
Associate Professor
Schools of Pharmacy and Medicine
Assistant Director, Atherosclerosis and
LDL-Apheresis Center
Kansas University Medical Center
Kansas, KS

James M. Falko, MD
Clinical Professor of Medicine
Endocrinology/Lipid Clinic
University of Colorado Hospital
Denver, CO

FH and Present Day Management- Why This Disease is Vital to Treat

Patrick M. Moriarty, MD


Antisense Therapy and FH: Mechanism of Action

James M. Backes, PharmD


A Fresh Look at New Treatment Options for FH- Reviewing the Data

James M. Falko, MD


FH Case Study

Patrick M. Moriarty, MD


Average: 5 (1 vote)
Activity Classification

This activity is instructional only and may not be taken for credit.

Content Domain
This activity falls under the following content domain(s):

Learning Objectives
This activity teaches to the following learning objective(s):

  1. Describe the pathophysiology of familial hypercholesterolemia and the role of apolipoprotein B, proprotein convertase subtilisin/kexin type 9 (PCSK9), microsomal transfer protein inhibitor (MTP) and lipoprotein(a) in lipid homeostasis.
  2. Describe the prevalence and associated risk of familial hypercholesterolemia (FH) in order to increase awareness and understanding of the disease;
  3. Evaluate the clinical effects, safety and efficacy data for current and new treatment options for FH patients.
  4. Implement management strategies to improve the care of patients with FH and reduce their elevated risk of CHD

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service